Современные возможности индивидуализации лекарственной терапии рака молочной железы
- Авторы: Переводчикова Н.И1, Стенина М.Б.1
-
Учреждения:
- ФГБУ «Российский онкологический научный центр им. Н.Н. Блохина» Минздрава России
- Выпуск: Том 21, № 1-2 (2016)
- Страницы: 18-25
- Раздел: Статьи
- URL: https://journals.rcsi.science/1028-9984/article/view/40284
- DOI: https://doi.org/10.18821/1028-9984-2015-21-1-18-25
- ID: 40284
Цитировать
Полный текст
Аннотация
В работе рассмотрены основные итоги конференции по раннему раку молочной железы (РМЖ) 2015 г. (Санкт-Галленский консенсус), а также последние наиболее значимые результаты изучения противоопухолевых препаратов при диссеминированном РМЖ.
Полный текст
Открыть статью на сайте журналаОб авторах
Н. И Переводчикова
ФГБУ «Российский онкологический научный центр им. Н.Н. Блохина» Минздрава России115478, г. Москва, Россия
Марина Борисовна Стенина
ФГБУ «Российский онкологический научный центр им. Н.Н. Блохина» Минздрава России
Email: mstenina@mail.ru
доктор медицинских наук, ведущий научный сотрудник отделения клинической фармакологии и химиотерапии НИИ клинической онкологии 115478, г. Москва, Каширское шоссе, д. 24
Список литературы
- Perou C.M., Sorlie T., Eisen M.B. et al. Molecular portraits of human breast cancer. Tumors Nature. 200; 406: 747-52.
- Sorlie T., Perou C.M., Tibshirani R. et al. Gene expression patterns of breast carcinoma distinguist tumor subclasses with clinical inplications. Proc. Natl. Acad. Sci. USA. 2001; 98: 10 569-74.
- Sorlie T., Tibshirani R., Parker J. et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl. Acad. Sci. USA. 2003; 100: 8418-23.
- Sortiriou C, Neo S.Y., Mc Shane L.M. et al. Breast cancer classification and prognosis based on gene expression profiles from population based study. Proc. Natl. Acad. Sci. USA. 2003; 100: 10 393-8.
- Perou C.M., Molecular stratification of triple negative breast cancer. Oncologist. 2011; 16 (Suppl. 1): 61-70.
- Prat A., Parker J.S., Karginova O et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res. 2010; 12: R68.
- Wigelt B., Mackay A., A’Hern R. et al. Breast cancer molecular profiling with single sample predictors. Lancet Oncol. 2010; 11: 339-49.
- Coates A.S., Winer E.P., Goldhirsh A et al. Tailoring therapiesimproving the management of early breast cancer. St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann. Oncol. Adv. Access published May 4 2015/ http://anonc.oxfordjournal.org
- Goldhirsh A., Wood W.C., Coates A.S et al. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann. Oncol. 2011; 22: 1736-47.
- Жукова Л.Г. Рак молочной железы с тройным негативным фенотипом у российской популяции больных. Клинико-морфологические особенности. Вопросы онкологии. 2015; 2: 189-94.
- Lehmann R.D., Bauer L.A., Chen I et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J. Clin. Invest. 2011: 121: 2750-67.
- Lehmann B.D., Pietenpol J.A., Tan A.R. Triple-negative breast cancer: molecular subtypes and new targets for therapy. Clin. Cancer Res. 2013; 35: е31-9.
- Masuda H., Baggerly K.A., Wang Y. et al. Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. Clin. Cancer Res. 2013; 19: 5533-40.
- Gucalp A., Tolaney S.M., Isakoff S. et al. Targeting the androgen receptor (AR) in women with AR+ ER-/PR- metastatic breast cancer (MBC). J. Clin. Oncol. 2012; 30 (Suppl.): Abstr. 1006.
- Traina T.A., Miller K., Yardley D.A. et al. Results from a phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer (TNBC). J. Clin. Oncol. 2015; 33 (Suppl): ASCO Abstr. 1003.
- Parker J.S., Peterson A.C., Tudor I.C. et al. A novel biomarker to predict sensitivity to enzalutamide (ENZA) in TNBC. J. Clin. Oncol. 2015; 33 (15, Suppl.): 1083.
- O’Sullivan C.C., Bradbury I., Campbell C. Efficacy of adjuvant trastuzumab for patients with human epidermal growth factor receptor 2-positive early breast cancer and tumors ≤ 2 cm: A meta-analysis of the randomized trastuzumab trials. J. Clin. Oncol. 2015; 33 (24): 2600-8.
- Семиглазов В.Ф., Палтуев Р.М., Семиглазов В.В. и др. Общие рекомендации по лечению раннего рака молочной железы St Gallen 2015, адаптированные экспертами Российского общества онкомаммологов. Опухоли женской репродуктивной системы. 2015; 15 (3): 43-60.
- Chan A., Delaloge S., Holmes F.A. et al. Neratinib after adjuvant chemotherapy and trastuzumab in HER2-positive early breast cancer: primary analysis at 2 years of a phase 3, randomized, placebo-controlled trial (ExteNET). J. Clin. Oncol. 2015; 33 (Suppl.): ASCO Abstr. 508.
- Swain S., Kim S., Cortes J. et al. Final overall survival analysis from the CLEOPATRA study of first-line pertuzumab, trastuzumab and docetaxel in pts with HER2-positive metastatic breast cancer. ESMO. 2014; 3500_PR.
- Blackwell K.L., Miles D., Gianni L. et al. Primary results from EMILIA, a phase III study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in HER2-positive locally advanced or metastatic breast cancer (MBC) previously treated with trastuzumab and a taxane. J. Clin. Oncol. 2012; 30 (Suppl.): Abstr. LBA1.
- Verma S., Miles D., Gianni L. et al. Trastuzumab emtansine for her2-positive advanced breast cancer. N. Engl. J. Med. 2012; 367 (19): 1783-91.
- Ellis P.A., Barrios C.H., Eiermann W., Toi M., Im Y.H., Conte P.F. et al. Phase III, randomized study of trastuzumab emtansine (T-DM1) ± pertuzumab (P) vs trastuzumab + taxane (HT) for first-line treatment of HER2-positive MBC: Primary results from the MARIANNE study. J. Clin. Oncol. 2015; 33 (Suppl.): Abstr. 507.
- Pagani O., Regan M.M., Walley B.A., Fleming G.F. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N. Engl. J. Med. 2014; 371 (2): 107-18.
- Francis P.A., Regan M.M., Fleming G.F. et al. adjuvant ovarian suppression in premenopausal breast cancer. N. Engl. J. Med. 2015; 372: 436-46.
- Finn R.S., Crown J.P., Lang I. et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first line treatment of oestrogen receptorpositive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol. 2015; 16: 25-35.
- Turner N.C., Ro J., Andre F. et al. Palbociclib in hormonereceptor-positive advanced breast cancer. DOI: 1056/NEJMoa1505270.
- Gnant M., Pfeiler G., Dubsky P.C. et al. Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo controlled trial. www.thelancet. com. Published online June 1, 2015 http://dx.doi.org/10.1016/S0140-6736(15)60995-3.